Jinxin Fertility Group Limited (abbreviation: JXR) disclosed a fresh share buy-back in its Next Day Disclosure Return dated 18 September 2026.

Key transaction • On 18 September 2026, JXR repurchased 1.34 million ordinary shares on the Hong Kong Stock Exchange at prices between HKD 2.09 and HKD 2.11, for a total consideration of HKD 2.80 million. • The repurchased stock is being held as treasury shares; none has yet been cancelled.

Capital structure after the trade • Issued shares (excluding treasury shares) fell by 1.34 million, or 0.05%, to 2.68 billion. • Treasury shares rose to 26.46 million. • Total issued shares remain unchanged at 2.71 billion.

Progress under current mandate • The present repurchase mandate, approved on 25 June 2026, authorises JXR to buy back up to 262.51 million shares. • Cumulative on-market repurchases under this mandate stand at 39.01 million shares, equivalent to 1.49% of the issued share capital on the mandate date. • A 30-day moratorium on new share issuance or treasury-share sales runs until 18 October 2026.

Pending cancellations • In addition to treasury stock, JXR has 92.47 million shares repurchased between 27 March and 25 August 2026 that are earmarked for cancellation but had not been cancelled as of 18 September 2026.

Pricing snapshot • The 18 September buy-back was executed at a volume-weighted average price of HKD 2.10 per share, compared with an average HKD 2.29–HKD 1.97 range for earlier repurchases awaiting cancellation.

Implications The latest buy-back marginally reduces JXR’s free-float while increasing its treasury share holdings. With approximately 223.51 million shares still available under the current mandate, the company retains capacity for further repurchases before the authorisation lapses or is renewed.